These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28891142)

  • 1. Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity.
    Neff LM; Broder MS; Beenhouwer D; Chang E; Papoyan E; Wang ZW
    Clin Obes; 2017 Dec; 7(6):337-346. PubMed ID: 28891142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
    Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
    Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.
    Liu SC; Tu YK; Chien MN; Chien KL
    Diabetes Obes Metab; 2012 Sep; 14(9):810-20. PubMed ID: 22486990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
    Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ
    Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials.
    Wu T; Wong CKH; Lui DTW; Wong SKH; Lam CLK; Chung MSH; McAllister DA; Welbourn R; Dixon JB
    BJS Open; 2023 Jul; 7(4):. PubMed ID: 37542473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.
    Handelsman Y; Fain R; Wang Z; Li X; Fujioka K; Shanahan W
    Postgrad Med; 2016 Nov; 128(8):740-746. PubMed ID: 27659698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh-Franco D; McLaughlin-Middlekauff J; Elrod S; Harrington C
    Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D; Cummins E; Royle P; Waugh N
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Bohula EA; Scirica BM; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Kanevsky E; Murphy SA; Leiter LA; Dwyer JP; Corbalan R; Hamm C; Kaplan L; Nicolau JC; Ophuis TO; Ray KK; Ruda M; Spinar J; Patel T; Miao W; Perdomo C; Francis B; Dhadda S; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
    Lancet; 2018 Nov; 392(10161):2269-2279. PubMed ID: 30293771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.